Navigation Links
Arete Therapeutics Presents Positive Clinical and Preclinical Data for AR9281
Date:6/9/2009

er), thus furthering the understanding of the mechanism of action of this novel drug candidate.

AR9281 Phase II Program Underway

Arete is conducting a Phase IIa multicenter, double-blind, placebo-controlled study of AR9281 in pre-diabetic patients with impaired glucose tolerance, mild obesity and mild to moderate hypertension. All 150 enrolled patients will be treatment-naive for type 2 diabetes medications. The trial is evaluating two schedules of AR9281 and placebo using a parallel design to determine the feasibility of twice-a-day dosing. Each patient receives 28 days of treatment. Endpoints for the trial include safety, tolerability, reduction of blood pressure and various measures of glucose and lipid metabolism, with results expected in the first quarter of 2010.

The Phase I clinical program for AR9281, consisting of two double-blind, placebo-controlled studies, demonstrated that AR9281 was safe and well tolerated in healthy volunteers. The studies met all safety, tolerability, pharmacokinetic and pharmacodynamic endpoints. In addition, AR9281 has shown favorable results in various published and proprietary in vitro and in vivo assays for potency, selectivity, efficacy, ADME, toxicity and safety.

About AR9281

AR9281, an orally-administered soluble epoxide hydrolase (sEH) inhibitor, operates within the third branch of the arachidonic acid pathway and represents a novel and potentially more effective approach to treating type 2 diabetes, hypertension and inflammatory disease. The first two branches of this critical regulatory pathway have been targeted by several commercially successful marketed anti-inflammatory drugs including Aspirin(R) (acetylsalicylic acid), Motrin(R) (ibuprofen), Singulair(R) (montelukast) and Celebrex(R) (celecoxib). AR9281 has demonstrated an excellent safety profile and activity in multiple animal models
'/>"/>

SOURCE Arete Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. CareTech Receives National Recognition in 2009 Aster Awards for Medical Marketing Excellence
2. CareTech Solutions Launches Robust Service Desk Solution to Support Clinical Applications and Technology within Continuum Health Partners Hospitals
3. CareTech Solutions Caps Banner Year by Signing Pennsylvanias Lehigh Valley Health Network, Tennessees Covenant Health, and Ohios Marietta Memorial Hospital to Provide Web Services
4. Arete Therapeutics Initiates Phase IIa Clinical Trial for AR9281, a Novel s-EH Inhibitor to Treat Type 2 Diabetes
5. EnovateIT Partners with CareTech Solutions to Create a Custom Product for Crittenton Hospital Medical Center, One of the Nation's Most Wired Hospitals
6. CareTech Solutions Named Best in KLAS for Extensive IT Outsourcing Services
7. Nationally Recognized Diabetes Specialist Dr. Steven Edelman to Provide Educational Articles on Diabetes to MyCareTeam's Website Community
8. CareTech Solutions Service Desk Equals Help Desk Plus
9. Arete Therapeutics Appoints Donald Santel to Board of Directors
10. Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent
11. CareTech Solutions Executive to Conduct Presentation on Creating a Healthy Revenue Cycle at AHIMA Convention and Exhibit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... United Theological Seminary is pleased to welcome two ... Peter J. Bellini. Both began their teaching duties on ... Director of Non-Degree Programs, Mark Abbott, who begins his ... Assistant Professor of New Testament, received a Ph.D. from ... Temple Judaism, and Greek courses. His research interests are ...
(Date:7/31/2014)... July 31, 2014 Cosmetic Town is ... Plastic Surgeons to consumers considering cosmetic treatments. The ... peers whose goal is to educate prospective patients on ... selected through a validated referral system that helps patients ... best in their respective fields. , Cosmetic Town ...
(Date:7/31/2014)... The VitaSleep FDA cleared anti-snoring ... provide an easier breathing capacity by slightly adjusting the ... people can breathe easier and helps reduce or even ... that it can meet the needs of each individual ... shared by actual customer reviews. Johathan R. from ...
(Date:7/31/2014)... Miami, FL (PRWEB) July 31, 2014 ... (LMS) which continues to help healthcare agencies to ... help companies and agencies meet their accreditation ... with competency based training. , Healthcare administrators ... a few clicks of the mouse. Courses can ...
(Date:7/31/2014)... Andrie, Inc. V. Dept. of Treasury, Mich. S. Ct., ... made the determination that a purchaser of tangible goods in ... unable to prove during an audit that sales tax ... of Appeals decision on whether a purchaser bears the burden ... from Michigan sellers. The Court states “in order to be ...
Breaking Medicine News(10 mins):Health News:Growing Seminary Welcomes New Faculty 2Health News:The New Doctors’ Directory, Cosmetic Town Does the Research for Consumers of Plastic Surgeries 2Health News:New Dental Device Reviews to Stop Snoring by VitalSleep 2Health News:Company Helps Healthcare Agencies to Pass Inspections and Audits 2Health News:Company Helps Healthcare Agencies to Pass Inspections and Audits 3Health News:Taxpayer Failing To Prove Sales Tax Was Paid At Time Of Purchase Results In Use Tax Due 2Health News:Taxpayer Failing To Prove Sales Tax Was Paid At Time Of Purchase Results In Use Tax Due 3
... Dr. Roberto Giraldo, an American physician who addressed ... malnutrition was one of the key factors that ... His website (www.robertogiraldo.com) says, "Aids is neither an ... a toxic-nutritional syndrome caused by the alarming worldwide ...
... as the time period immediately prior to menopause beginning ... year after the last menstrual periods, is a time ... a history of mood// disorders. Earlier studies have shown ... age (considered early) were two to three times more ...
... 61 previous studies of blood pressure and cardiovascular disease, which ... regardless of age and even if readings are in the ... reducing risk of strokes and heart attacks. ,The study ... that out of the 120,000 who died, 56,000 suffered fatal ...
... cessation has often been connected to gaining excess weight. ... gain could be related to the hormone leptin, which ... on assumptions that leptin levels were high during smoking ... smoking, the leptin levels plummet leading to weight gain. ...
... A supplemental new drug application (sNDA) for Valtrex (valacyclovir ... and Drug Administration (FDA) for the treatment of cold ... which also added that this new application for Valtrex// ... to shorten the duration of a cold sore outbreak. ...
... the most common reason which results in fatal complications ... potentially dangerous bug which causes this type of ... found naturally in the environment and survives drying and ... periods. This bacterium which is not harmful to healthy ...
Cached Medicine News:Health News:Depressed women show signs of earlier onset of Perimenopause 2Health News:Machines take over the battle against hospital bugs 2
(Date:7/31/2014)...  A substantial share of pharmacy and therapeutics ... are included in formularies—say patient support resources from ... Manhattan Research study, Taking the Pulse® Formulary ... P&T committee members in hospitals, managed care organizations ... a high bar for these programs, requiring that ...
(Date:7/31/2014)... Lazarus Effect, a medical device company focused ... removal of blood clots, announced the closing of a ... EU commercialization of several approved Lazarus Effect devices, as ... Lazarus Cover™ in the United States ... the value of our novel, platform technology as well ...
(Date:7/31/2014)... , July 31, 2014 For its innovative ... California , Art,s-Way Scientific has earned a Modular ... With competition in over 30 categories, MBI,s contest is ... members, which include building manufacturers, dealers, and product and ... excellent example the capability of our team," said ...
Breaking Medicine Technology:Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 2Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 3Lazarus Effect Closes $5 Million Financing 2Art's Way Scientific Earns Prestigious Modular Building Institute Award 2Art's Way Scientific Earns Prestigious Modular Building Institute Award 3Art's Way Scientific Earns Prestigious Modular Building Institute Award 4
... , SAN MATEO, Calif., Oct. 1 Corthera Inc. ... (FDA) has granted Fast Track designation to relaxin, the ... failure (AHF). The Fast Track program facilitates the development ... treat serious or life-threatening conditions and that demonstrate the ...
... Oct. 1 Health Strategies Group, a leading ... industries, has just launched Oncology Performance Edge, a new ... in the oncology field improve brand performance by understanding ... oncology market is significantly different from others, with unique ...
Cached Medicine Technology:Corthera's Relaxin Receives FDA Fast Track Designation for the Treatment of Acute Heart Failure 2Corthera's Relaxin Receives FDA Fast Track Designation for the Treatment of Acute Heart Failure 3Health Strategies Group Introduces Oncology Performance Edge 2Health Strategies Group Introduces Oncology Performance Edge 3
The adult blanket provides full coverage for patients of all sizes. The generous size and versatility of these blankets include extra material for the shoulders and feet. The foot drape also reduces ...
The cath lab blanket, designed for use in the Cardiac Cath Lab, surrounds the patient with warm air and allows unrestricted access to the femoral artery....
The Bair Hugger outpatient blanket makes it easy to give your patients the benefit of prewarming and enhance patient comfort during outpatient procedures....
The fabric is antistatic and non-linting and is both oil and water repellent.These superior blankets are an environmental friendly alternative to disposable blankets....
Medicine Products: